Eduardo Vilar-Sanchez, M.D., Ph.D.
Department of Clinical Cancer Prevention, Division of Cancer Prevention and Population Sciences
Present Title & Affiliation
Primary Appointment
Department Chair ad interim, Department of Clinical Cancer Prevention, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX
Professor (Term Tenure), Department of Clinical Cancer Prevention, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Professor (Term Tenure), Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Affiliate Faculty, Department of Clinical Cancer Genetics Program, The University of Texas MD Anderson Cancer Center, Houston, TX
Regular Member, Department of Cancer Biology, MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX
Regular Member, Department of Quantitative Sciences, MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX
Research Interests
Dr. Vilar-Sanchez is a physician-scientist and a medical oncologist by training. Dr. Vilar’s clinical expertise and practice are devoted to the care of patients and families diagnosed with hereditary cancer syndromes with a special emphasis in Lynch Syndrome and Familial Adenomatous Polyposis. His long term goal is to contribute to the understanding of colorectal cancer carcinogenesis at the molecular and cellular level and leverage this information to develop novel cancer interception strategies for these genetic conditions. In order to accomplish this overarching goal, the Vilar research group has contributed to the characterization of the genomic and transcriptomic landscape of colorectal premalignancy by both utilizing next-generation sequencing and systems biology tools, which has allowed them to identify new genes cooperating in carcinogenesis (e.g. CNOT3 ), and also identifying novel drug targets for clinical trial implementation (e.g. Naproxen, neoantigens for vaccines). In addition, the Vilar Group has participated in the development of ex vivo models to better recapitulate the biology of the uninvolved adjacent mucosa and premalignancy. Finally, Dr. Vilar has designed investigator-initiated clinical trials in Lynch Syndrome that have been funded by the National Cancer Institute through the N01 (now UG1) Chemoprevention Consortium for early drug development in prevention.
Education & Training
Degree-Granting Education
| 2009 | University Miguel Hernandez, Alicante, ESP, PHD, Anatomy |
| 2007 | Spanish National Cancer Center (CNIO), Madrid, ESP, MS, Molecular Oncology |
| 2002 | University Miguel Hernandez Medical School, Alicante, ESP, MD, Medicine |
Postgraduate Training
| 2009-2011 | Clinical Fellowship, Hematology/Oncology, University of Michigan, Ann Arbor, MI |
| 2007-2009 | Research Fellowship, Molecular Medicine & Genetics, University of Michigan, Ann Arbor, MI |
| 2004-2007 | Clinical Residency, Medical Oncology, Vall d'Hebron University Hospital, Barcelona |
| 2003-2004 | Clinical Internship, Internal Medicine, Vall d'Hebron University Hospital, Barcelona |
Board Certifications
| 2020 | American Board of Internal Medicine, Medical Oncology |
| 2019 | American Board of Internal Medicine, Internal Medicine |
Experience & Service
Academic Appointments
Associate Professor (Term Tenure), Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2018 - 2023
Associate Professor (Term Tenure), Department of Clinical Cancer Prevention, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, 2018 - 2023
Regular Member, Department of Genetics and Epigenetics, MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX, 2017 - 2019
Director, Department of Human and Molecular Genetics, MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX, 2016 - 2018
Co-Director, Department of Human and Molecular Genetics Graduate Program, MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX, 2015 - 2016
Assistant Professor (Tenure Track), Department of Clinical Cancer Prevention, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012 - 2018
Assistant Professor (Tenure Track), Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012 - 2018
Administrative Appointments/Responsibilities
Colorectal Cancer Moon Shot, Executive Leadership Team, Co-Leader, Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019 - Present
Pre-Cancer Atlas, STRIDE Initiative, Co-Leader, Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, 2018 - Present
Honors & Awards
| 2022 | Margaret and James A. Elkins, Jr. Faculty Achievement Award in Cancer Prevention, The University of Texas MD Anderson Cancer Center |
| 2021 | Champions and Changemakers of Cancer Prevention, Early Detection and Symptom Science, National Cancer Institute (NCI) |
| 2020 | American Association of Clinical Investigation (Honors Society), Elected Member |
| 2020 | Faculty Scholar Award, The University of Texas MD Anderson Cancer Center |
| 2019 | Bert Vogelstein Lectureship, The Collaborative Group of the Americas on Inherited Colorectal Cancer |
| 2018 | The Best of AACR Journals Collection, American Association for Cancer Research |
| 2018 | President's Recognition of Faculty Excellence, Research Excellence, The University of Texas MD Anderson Cancer Center |
| 2017 | Regular Member, Five-Year Renewal with Commendation, The University of Texas Graduate School of Biomedical Sciences, Houston, TX |
| 2014 | Faculty Educator of the Month - September 2014, University of Texas MD Anderson Cancer Center |
| 2011 | Young Investigator Award, American Society of Clinical Oncology |
| 2011 | Extraordinary Award for PhD dissertations, Miguel Hernandez University, Alicante, Spain |
| 2010 | Excellence in Research Award, Hematology/Oncology Fellowship Program, University of Michigan |
| 2009 | Merit Award, American Society of Clinical Oncology |
| 2009 | Outstanding Research Award, Internal Medicine Research Symposium, University of Michigan |
| 2008 | Merit Award, American Society of Clinical Oncology |
| 2007 | 'la Caixa' Fellowship, 'la Caixa' Foundation, Barcelona, Spain |
| 2002 | Academic Grant for Undergraduate Students, Department of Anatomy & Histology, Miguel Hernandez University, Alicante, Spain |
Selected Publications
Peer-Reviewed Articles
- Schiller JT, Lowy DR, Frazer IH, Finn OJ, Vilar E, Lyerly HK, Gnjatic S, Zaidi N, Ott PA, Balachandran VP, Dietrich PY, Migliorini D, Vonderheide RH, Domchek SM. Cancer vaccines. Cancer Cell 40(6):559-564, 2022. PMID: 35700704.
- Orouji E, Raman AT, Singh AK, Sorokin A, Arslan E, Ghosh AK, Schulz J, Terranova C, Jiang S, Tang M, Maitituoheti M, Callahan SC, Barrodia P, Tomczak K, Jiang Y, Jiang Z, Davis JS, Ghosh S, Lee HM, Reyes-Uribe L, Chang K, Liu Y, Chen H, Azhdarinia A, Morris J, Vilar E, Carmon KS, Kopetz SE, Rai K. Chromatin state dynamics confers specific therapeutic strategies in enhancer subtypes of colorectal cancer. Gut 71(5):938-949, 2022. e-Pub 2021. PMID: 34059508.
- Ozirmak Lermi N, Gray SB, Bowen CM, Reyes-Uribe L, Dray BK, Deng N, Harris RA, Raveendran M, Benavides F, Hodo CL, Taggart MW, Colbert Maresso K, Sinha KM, Rogers J, Vilar E. Comparative molecular genomic analyses of a spontaneous rhesus macaque model of mismatch repair-deficient colorectal cancer. PLoS Genet 18(4):e1010163. e-Pub 2022. PMID: 35446842.
- Gebert J, Gelincik O, Oezcan-Wahlbrink M, Marshall JD, Hernandez-Sanchez A, Urban K, Long M, Cortes E, Tosti E, Katzenmaier EM, Song Y, Elsaadi A, Deng N, Vilar E, Fuchs V, Nelius N, Yuan YP, Ahadova A, Sei S, Shoemaker RH, Umar A, Wei L, Liu S, Bork P, Edelmann W, von Knebel Doeberitz M, Lipkin SM, Kloor M. Recurrent Frameshift Neoantigen Vaccine Elicits Protective Immunity With Reduced Tumor Burden and Improved Overall Survival in a Lynch Syndrome Mouse Model. Gastroenterology 161(4):1288-1302.e13, 2021. e-Pub 2021. PMID: 34224739.
- Bommi PV, Bowen CM, Reyes-Uribe L, Wu W, Katayama H, Rocha P, Parra ER, Francisco-Cruz A, Ozcan Z, Tosti E, Willis JA, Wu H, Taggart MW, Burks JK, Lynch PM, Edelmann W, Scheet PA, Wistuba II, Sinha KM, Hanash SM, Vilar E. The Transcriptomic Landscape of Mismatch Repair-Deficient Intestinal Stem Cells. Cancer Res 81(10):2760-2773, 2021. e-Pub 2021. PMID: 34003775.
- Reyes-Uribe L, Wu W, Gelincik O, Bommi PV, Francisco-Cruz A, Solis LM, Lynch PM, Lim R, Stoffel EM, Kanth P, Samadder NJ, Mork ME, Taggart MW, Milne GL, Marnett LJ, Vornik L, Liu DD, Revuelta M, Chang K, You YN, Kopelovich L, Wistuba II, Lee JJ, Sei S, Shoemaker RH, Szabo E, Richmond E, Umar A, Perloff M, Brown PH, Lipkin SM, Vilar E. Naproxen chemoprevention promotes immune activation in Lynch syndrome colorectal mucosa. Gut 70(3):555-566, 2021. e-Pub 2020. PMID: 32641470.
- Jakubek YA, Chang K, Sivakumar S, Yu Y, Giordano MR, Fowler J, Huff CD, Kadara H, Vilar E, Scheet P. Large-scale analysis of acquired chromosomal alterations in non-tumor samples from patients with cancer. Nat Biotechnol 38(1):90-96, 2020. e-Pub 2019. PMID: 31685958.
- Chang K, Willis JA, Reumers J, Taggart MW, San Lucas FA, Thirumurthi S, Kanth P, Delker DA, Hagedorn CH, Lynch PM, Ellis LM, Hawk ET, Scheet PA, Kopetz S, Arts J, Guinney J, Dienstmann R, Vilar E. Colorectal premalignancy is associated with consensus molecular subtypes 1 and 2. Ann Oncol 29(10):2061-2067, 2018. PMID: 30412224.
- Chang K, Taggart MW, Reyes-Uribe L, Borras E, Riquelme E, Barnett RM, Leoni G, San Lucas FA, Catanese MT, Mori F, Diodoro MG, You YN, Hawk ET, Roszik J, Scheet P, Kopetz S, Nicosia A, Scarselli E, Lynch PM, McAllister F, Vilar E. Immune Profiling of Premalignant Lesions in Patients With Lynch Syndrome. JAMA Oncol 4(8):1085-1092, 2018. e-Pub 2018. PMID: 29710228.
- Lo YH, Noah TK, Chen MS, Zou W, Borras E, Vilar E, Shroyer NF. SPDEF Induces Quiescence of Colorectal Cancer Cells by Changing the Transcriptional Targets of β-catenin. Gastroenterology 153(1):205-218.e8, 2017. e-Pub 2017. PMID: 28390865.
- Crespo M, Vilar E, Tsai SY, Chang K, Amin S, Srinivasan T, Zhang T, Pipalia NH, Chen HJ, Witherspoon M, Gordillo M, Xiang JZ, Maxfield FR, Lipkin S, Evans T, Chen S. Colonic organoids derived from human induced pluripotent stem cells for modeling colorectal cancer and drug testing. Nat Med 23(7):878-884, 2017. e-Pub 2017. PMID: 28628110.
- de Rosa N, Rodriguez-Bigas MA, Chang GJ, Veerapong J, Borras E, Krishnan S, Bednarski B, Messick CA, Skibber JM, Feig BW, Lynch PM, Vilar E, You YN. DNA Mismatch Repair Deficiency in Rectal Cancer: Benchmarking Its Impact on Prognosis, Neoadjuvant Response Prediction, and Clinical Cancer Genetics. J Clin Oncol 34(25):3039-46, 2016. e-Pub 2016. PMID: 27432916.
- Borras E, San Lucas FA, Chang K, Zhou R, Masand G, Fowler J, Mork ME, You YN, Taggart MW, McAllister F, Jones DA, Davies GE, Edelmann W, Ehli EA, Lynch PM, Hawk ET, Capella G, Scheet P, Vilar E. Genomic Landscape of Colorectal Mucosa and Adenomas. Cancer Prev Res (Phila) 9(6):417-27, 2016. e-Pub 2016. PMID: 27221540.
- Mork ME, You YN, Ying J, Bannon SA, Lynch PM, Rodriguez-Bigas MA, Vilar E. High Prevalence of Hereditary Cancer Syndromes in Adolescents and Young Adults With Colorectal Cancer. J Clin Oncol 33(31):3544-9, 2015. e-Pub 2015. PMID: 26195711.
- San Lucas FA, Fowler J, Chang K, Kopetz S, Vilar E, Scheet P. Cancer in silico drug discovery: a systems biology tool for identifying candidate drugs to target specific molecular tumor subtypes. Mol Cancer Ther 13(12):3230-40, 2014. e-Pub 2014. PMID: 25349306.
- Vilar E, Bartnik CM, Stenzel SL, Raskin L, Ahn J, Moreno V, Mukherjee B, Iniesta MD, Morgan MA, Rennert G, Gruber SB. MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers. Cancer Res 71(7):2632-42, 2011. e-Pub 2011. PMID: 21300766.
- Vilar E, Mukherjee B, Kuick R, Raskin L, Misek DE, Taylor JM, Giordano TJ, Hanash SM, Fearon ER, Rennert G, Gruber SB. Gene expression patterns in mismatch repair-deficient colorectal cancers highlight the potential therapeutic role of inhibitors of the phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway. Clin Cancer Res 15(8):2829-39, 2009. e-Pub 2009. PMID: 19351759.
- Vilar E, Scaltriti M, Balmaña J, Saura C, Guzman M, Arribas J, Baselga J, Tabernero J. Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines. Br J Cancer 99(10):1607-12, 2008. e-Pub 2008. PMID: 18941461.
Invited Articles
- Spira A, Yurgelun MB, Alexandrov L, Rao A, Bejar R, Polyak K, Giannakis M, Shilatifard A, Finn OJ, Dhodapkar M, Kay NE, Braggio E, Vilar E, Mazzilli SA, Rebbeck TR, Garber JE, Velculescu VE, Disis ML, Wallace DC, Lippman SM. Precancer Atlas to Drive Precision Prevention Trials. Cancer Res 77(7):1510-1541, 2017. PMID: 28373404.
- Spira A, Disis ML, Schiller JT, Vilar E, Rebbeck TR, Bejar R, Ideker T, Arts J, Yurgelun MB, Mesirov JP, Rao A, Garber J, Jaffee EM, Lippman SM. Leveraging premalignant biology for immune-based cancer prevention. Proc Natl Acad Sci U S A 113(39):10750-8, 2016. e-Pub 2016. PMID: 27638202.
- Vilar E, Tabernero J. Molecular Dissection of Microsatellite Instable Colorectal Cancer. Cancer Discov 3(5):502-11, 2013. e-Pub 2013. PMID: 23454900.
- Vilar E, Perez-Garcia J, Tabernero J. Pushing the envelope in the mTOR pathway: the second generation of inhibitors. Mol Cancer Ther 10(3):395-403, 2011. e-Pub 2011. PMID: 21216931.
- Dienstmann R, Vilar E , Tabernero J. Molecular predictors of response to chemotherapy in colorectal cancer. Cancer J 17(2):114-26, 2011. PMID: 21427555.
- Vilar E, Gruber SB. Microsatellite instability in colorectal cancer-the stable evidence. Nat Rev Clin Oncol 7(3):153-62, 2010. e-Pub 2010. PMID: 20142816.
- Durán I, Salazar R, Casanovas O, Arrazubi V, Vilar E, Siu LL, Yao J, Tabernero J. New drug development in digestive neuroendocrine tumors. Ann Oncol 18(8):1307-13, 2007. e-Pub 2007. PMID: 17301070.
Editorials
- Willis JA, Vilar E. Pharmacogenomics: Time to re-think its role in Precision Medicine. Ann Oncol 29(2):293-295, 2018. PMID: 29236957.
- Barnett RM, Vilar E. Targeted Therapy for Cancer-Associated Fibroblasts: Are We There Yet?. J Natl Cancer Inst 110(1), 2018. PMID: 28922783.
- Willis JA, Vilar E. Refining Prognosis in Early-Stage Colorectal Cancer: One or multiple genes at a time?. Ann Oncol 28(8):1686-1688, 2017. PMID: 28549076.
- Vilar E, Stoffel EM. Universal Genetic Testing for Younger Patients With Colorectal Cancer. JAMA Oncol 3(4):448-449, 2017. PMID: 27978567.
- Vilar E, Maresso KC, Hawk ET. Aspirin for Cancer Prevention: One Step Closer. JAMA Oncol 2(6):770-1, 2016. PMID: 26939883.
- Colbert Maresso K, Vilar E, Hawk ET. Urinary PGE-M in Colorectal Cancer: Predicting More than Risk?. Cancer Prev Res (Phila) 7(10):969-72, 2014. PMID: 25070664.
- Vilar E, Tabernero J. Cancer: Pinprick diagnostics. Nature 486(7404):482-3, 2012. PMID: 22739312.
- Vilar E, Tabernero J, Gruber SB. Micromanaging the classification of colon cancer: the role of the microRNAome. Clin Cancer Res 17(23):7207-9, 2011, 2011. PMID: 22019515.
Abstracts
- Uribe LR, Lin R, Stoffel EM, Samadder NJ, Lynch PM, Kanth P, Milne GL, Marnett LJ, Sepeda V, Liu DD, You YN, Vornik LA, Lee JJ, Richmond E, Umar A, Perloff M, Lipkin SM, Brown PB, Vilar E. A phase Ib biomarker trial of naproxen in patients at risk for DNA mismatch repair deficient colorectal cancer. AACR Annual Meeting 2018, Chicago, IL Cancer Res (2018) 78 (13_Supplement): CT065, 2018.
Book Chapters
- Barnett RM, Borras E, Samadder NJ, Vilar E. Chemoprevention in Hereditary Colorectal Cancer Syndromes. In: Hereditary Colorectal Cancer: Genetic Basis and Clinical Implications. Springer Nature: Switzerland, 349-366, 2018.
- Vilar E, Salazar R, Tabernero J. Medical Oncology Management of Hereditary Colorectal Cancer. In: Hereditary Colorectal Cancer: Genetic Basis and Clinical Implications. Springer Nature: Switzerland, 401-416, 2018.
- Mork M, Vilar E. MUTYH-Associated Polyposis. In: Intestinal Polyposis Syndromes Diagnoses and Management. Springer International Publishing: Cham, Switzerland, 25-32, 2016.
- JM Reyes, Vilar E. Epidemiology and Prevention. In: Medicina Interna Farreras. 18. Elsevier: Barcelona, Spain, 1084-85, 2016.
- Vilar E. Colorectal Cancer. In: Medicina Interna Farreras. 18. Elsevier: Barcelona, Spain, 1101-3, 2016.
- Bailey CE, Vilar E, You YNY. Adjuvant and Neoadjuvant Management of Cancer of the Colon and Rectum. In: ACS Surgery, Principles and Practice. Decker Intellectual Properties: Hamilton, ON Canada, 2014.
Letters to the Editor
- You YN, Rodriguez-Bigas MA, Das P, Healy M, Chiang YJ, George T, Vilar E. Comment on "A National Cancer Database Analysis of Microsatellite Instability and Pathologic Complete Response in Locally Advanced Rectal Cancer". Ann Surg.
- Mork ME, You YN, Vilar E. Reply to L.B. Saltz. J Clin Oncol 34: 1560-1, 2016.
Grant & Contract Support
| Date: | 2022 - 2027 |
| Title: | Cancer Immune-Interception in a Spontaneous Non-Human Primate Model of Lynch Syndrome |
| Funding Source: | NIH/NCI |
| Role: | Co-Principal Investigator |
| ID: | 1R01CA260761-01 |
| Date: | 2019 - 2024 |
| Title: | TORFP NN-2019, “Core Infrastructure Support” |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
| ID: | HHSN261201200034I / 75N91019F00129 |
| Date: | 2019 - 2024 |
| Title: | MD Anderson Cancer Center SPORE in Gastrointestinal Cancer: Project 2, Targeting STAT3 to Prevent Colorectal Cancer (CRC) in Hereditary Syndromes and Inflammatory Bowel Disease |
| Funding Source: | NIH/NCI |
| Role: | Project Principal Investigator |
| ID: | 1 P50 CA221707 |
| Date: | 2019 - 2022 |
| Title: | Preclinical PREVENT Cancer Program: Optimization of Dosing Regimens of Sulindac in Combination with Erlotinib for Small Intestinal and Colon Cancer Prevention |
| Funding Source: | NIH/NCI |
| Role: | Co-Principal Investigator |
| ID: | 75N91019D00021 |
| Date: | 2019 - 2026 |
| Title: | Cancer Center Support (CORE) Grant |
| Funding Source: | NIH/NCI |
| Role: | Program Leader |
| ID: | Cancer Center Support (CORE) Grant |
| Date: | 2018 - 2020 |
| Title: | Liquid biopsies in Early Diagnosis of Colorectal Cancer |
| Funding Source: | Rising Tide Foundation |
| Role: | Co-Investigator |
| ID: | LAB10-0334 |
| Date: | 2018 - 2024 |
| Title: | Neoantigen Vaccination for Lynch Syndrome Immunoprevention |
| Funding Source: | NIH/NCI |
| Role: | Co-Principal Investigator |
| ID: | U01CA233056 |
| Date: | 2018 - 2023 |
| Title: | Genetic and Dietary Interactions in MMR Deficient Colon Tumorigenesis |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |
| ID: | R01 CA222358 |
| Date: | 2017 - 2019 |
| Title: | A Phase II Enrichment Study of Panitumumab as a Single Agent or in Combination with Trametinib in Cetuximab-Refractory Stage IV Colorectal Cancer Patients |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |
| ID: | 2016-0338 |
| Date: | 2017 - 2023 |
| Title: | Uncovering the Role of Colorectal Stem Cells on Disease Penetrance in Lynch Syndrome |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
| ID: | R01 CA219463-01 |
| Date: | 2017 - 2020 |
| Title: | Uncovering Gene Expression Differences between Benign and Premalignant Colorectal Polyps |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
| ID: | R21 CA208461-01A |
| Date: | 2017 - 2020 |
| Title: | Determination of Dosing Regimens of Erlotinib in Combination with Sulindac for Prevention of Colorectal Cancer While Reducing Agent Toxicity |
| Funding Source: | NIH/NCI |
| Role: | Co-Principal Investigator |
| ID: | N01 HHSN2612015000181 |
| Date: | 2017 - 2024 |
| Title: | CCAR2 as a Target for Prevention of Colorectal Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |
| ID: | R01 CA122959-06A1 |
| Date: | 2015 - 2016 |
| Title: | Clinical Impact of Multi-gene Sequencing Panel Among Young Adults with Colorectal Cancer |
| Funding Source: | Clinical Innovator Award |
| Role: | Collaborator |
| Date: | 2014 - 2016 |
| Title: | Discovering New Chemopreventive Approaches in Familial Adenomatous Polyposis |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
| ID: | R03 CA176788-01A1 |
| Date: | 2013 - 2019 |
| Title: | A phase Ib biomarker trial of Naproxen in patients at risk for DNA Mismatch Repair Deficient Colorectal Cancer |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
| ID: | N01 HHSN261201200034I |
| Date: | 2013 - 2015 |
| Title: | Discovering new Targets for Chemoprevention in Familial Adenomatous Polyposis |
| Funding Source: | Duncan Family Institute |
| Role: | Principal Investigator |
| Date: | 2012 - 2012 |
| Title: | Developing Targeted Therapies for Microsatellite Instable Colorectal Cancers |
| Funding Source: | American Society of Clinical Oncology (ASCO) |
| Role: | Principal Investigator |
| ID: | N013428 |
| Date: | 2012 - 2018 |
| Title: | Research Initiation Funds |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | Principal Investigator |
Patient Reviews
CV information above last modified August 22, 2024